showed a synergistic antitumor response in vivo, upon treating a novel humanized nasopharyngeal carcinoma PDX mouse model with PD-L1 CAR-NK and an anti-PD-1 antibody (Nivolumab) (86). The gene discussed is CD274; the disease is nasopharyngeal carcinoma.